| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20558 | STOML3 inhibitor OB-1 Featured | OB-1 is a small-molecule inhibitor of STOML3 oligomerization that reverses pathological mechanical hypersensitivity in vivo; effectively inhibits the self-association of stomatin, STOML1 and STOML2 at 2 uM, but not podocin; reversibly reduces the sensitiv |
|
| DC11752 | iKIX1 | A small-molecule inhibitor of the interaction of the C. glabrata Pdr1 activation domain with the C. glabrata Gal11A KIX domain with Ki of 18 uM. |
|
| DC23027 | INP-0400 | A small-molecule inhibitor of type III secretion in Y. pseudotuberculosis, without affecting in vitro multiplication, causes a dose- and growth phase-dependent inhibition of C. trachomatis RB multiplication.. |
|
| DC11759 | AKCI | A small-molecule inhibitor that blocks the Aurora C/IκBα interaction (IC50=24.9 uM) and exerts antitumor activity in MDA-MB-231 breast cancer cells. |
|
| DC22553 | KIN-1408 | A small-molecule MAVS-dependent IRF3 agonist that shows antiviral activity against Flaviviridae, Filoviridae (Ebola virus), Orthomyxoviridae (influenza A virus), Arenaviridae (Lassa virus) and Paramyxoviridae (RSVs, Nipah virus). |
|
| DC11686 | (R)-CCX-777 | A small-molecule partial agonist of CXCR7 (ACKR3).. |
|
| DC11687 | (S)-CCX-777 | A small-molecule partial agonist of CXCR7 (ACKR3).. |
|
| DC11685 | CCX-777 | A small-molecule partial agonist of CXCR7 (ACKR3).. |
|
| DC22799 | ML-162 Featured | A small-molecule probe that selectively kills cells induced to express mutant RAS. |
|
| DC22800 | ML-210 Featured | A small-molecule probe that selectively kills cells induced to express mutant RAS. |
|
| DC21029 | Fusicoccin-A | A small-molecule stabilizer of 14-3-3 protein-protein interactions that stabilizes the complex between 14-3-3 and the stress response regulator GCN1. |
|
| DC22854 | PhiKan-083 | A small-molecule stabilizer of p53 mutant Y220C with Kd of 150 uM. |
|
| DC23009 | Gue-1654 | A small-molecule that inhibits Gβγ but not Gα signaling triggered upon activation of Gα(i)-βγ by the chemoattractant receptor OXE-R in both recombinant and human primary cells. |
|
| DC20886 | CGP-049090 | A small-molecule that specifically inhibits the interaction of β-catenin/LEF1 transcriptional complex in colon carcinoma cell lines. |
|
| DC11638 | BCI(NSC 150117) Featured | BCI is A small-molecule, allosteric inhibitor of DUSP6 (dual-specificity phosphatase 6) with IC50 of 12.3 uM; also inhibits human DUSP1 with IC50 of 11.5 uM; suppresses the ERK-induced activation of Dusp6 and regulates heart size in zebrafish. |
|
| DC22392 | BRD-4592 | A small-molecule, allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase (TrpAB). |
|
| DC21831 | Tepilamide fumarate | A small-molecule, fumaric acid ester (FAE) compound that is a prodrug of methyl hydrogen fumarate (also known as monomethyl fumarate), for the treatment of relapsing-remitting multiple sclerosis and plaque psoriasis.. |
|
| DC21244 | LMP-420 | A small-molecule, orally active inhibitor of TNF-α that reduces replication of HIV-1 (IC50=300 nM) and Mycobacterium tuberculosis in human cells. |
|
| DC26093 | PH-064 Featured | A sodium channel inhibitor.. |
|
| DC24093 | PF-915275 Featured | PF-915275 is a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (Ki ＜ 1 nM) with good preclinical pharmacokinetic properties.IC50 value: ＜ 1 nM (Ki)[2]Target: 11βHSD1in vitro: PF-915275 maintains potency in our cellular assay against human 11βHSD1 (HEK293, EC50 = 5 nM) and is selective against human 11βHSD2 (HEK293, 1.5% inhibition 10 μM). PF-915275 displays only weak affinity for the rodent choline transporter (Ki = 9.6 μM) and the hamster melatonin MT3 receptor (Ki = 9.6 μM) in the Cerep Bioprint screening panel. PF-915275 has good in vitro pharmacokinetic properties. In particular, PF-915275 is categorized as a low clearance compound (liver microsome assays) with high permeability (Caco2 assay). [2]in vivo: As a prelude to in vivo studies with PF-915275, the rat pharmacokinetic properties of this compound were determined. PF-915275 has an excellent pharmacokinetic profile characterized by low clearance, long half-life and good oral bioavailability. [2] |
|
| DC11774 | YM-53403 | A specific anti-respiratory syncytial virus (RSV) agent with EC50 of 0.2 uM in plaque reduction assays. |
|
| DC22642 | Sibiriline | A specific competitive RIPK1 inhibitor with IC50 of 1.03 uM, 100-fold less potent for RIPK3. |
|
| DC21394 | NOFD | A specific HIF asparaginyl hydroxylase (FIH) inhibitor with Ki of 83 uM, but not HIF prolyl hydroxylase (>1 mM). |
|
| DC23022 | PDZ1i Featured | A specific inhibitor of MDA-9/Syntenin activity that inhibits MDA-9/Syntenin binding to EGFRvIII. |
|
| DC23589 | CGP 37157 Featured | A specific inhibitor of mitochondrial Na(+)-Ca(2+) exchanger (mNCE) with IC50 of 1.5 uM in INS-1 cells. |
|
| DC22633 | SB 203580 hydrochloride | A specific p38 MAPK inhibitor with IC50 of 0.6 uM. |
|
| DC22835 | SCH 350581 | A specific small molecule inhibitor of CCR5, inhibits HIV-1 entry.. |
|
| DC22830 | SCH 350581 dihydrochloride | A specific small molecule inhibitor of CCR5, inhibits HIV-1 entry.. |
|
| DC20361 | Difopein | A specific, competitive inhibitor of 14-3-3/ligand interactions with high affinity. |
|
| DC22803 | M-443 | A specific, irreversible inhibitor of MLK-related kinase MRK (ZAK), does not inhibit Bcr-Abl. |
|
